Fentanyl Injectable Recalled for Lack of Sterility Assurance
Central Admixture Pharmacy Services is recalling 1,044 bags of fentanyl injectable solution due to lack of validated sanitization procedures that could compromise sterility assurance. The product affects healthcare facilities nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable opioid product due to lack of validated sanitization procedures. Fentanyl is a risk-of-harm product, and while no illnesses or injuries have been reported, the potential for serious harm from non-sterile injections meets the High severity criterion.
Plain-English summary
Central Admixture Pharmacy Services Inc is recalling 1,044 bags of fentanyl injectable solution (5000 mcg/250 mL). The product is supplied in sterile preparation bags for intravenous use and was distributed nationwide.
The manufacturer and FDA identified that the product lacks adequate assurance of sterility. Specifically, the sanitization cycles used in manufacturing lack validation data to ensure they are effective.
Fentanyl is a potent opioid used in clinical and hospital settings. Any potential compromise to sterility could pose a risk to patients who receive the product.
Healthcare facilities that received this product should stop using it and follow the recall instructions provided by Central Admixture Pharmacy Services Inc. Healthcare providers should monitor any patients who may have received fentanyl from these affected lots.
The recalled product
- Product
- fentaNYL in 0.9% sodium chloride, 5000 mcg/250 mL, (20 mcg/mL), 250 mL Bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2074-1
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Compounded Injectable
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 17-271115
- Exp. 7/25/2023
- 17-271398
- Exp. 7/30/2023
- 17-272278
- Exp. 8/14/2023
- 17-272449
- Exp. 8/16/2023
- 17-272521
- Exp. 8/17/2023
- 17-272900
- Exp. 8/23/2023
- 17-273146
- Exp. 8/29/2023
- 17-273236
- Exp. 8/30/2023
- 17-273404
- Exp. 9/3/2023
- 17-273678
- Exp. 9/6/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27